

Long term efficacy profile of Synolis V-A in patients affected by symptomatic hip osteoarthritis: The "SYCA" study. Preliminary data

U.Massafra*; E.Bizzi*; F Vacca*; F Giovannangeli*; S.Tormentaº; A.Migliore*
*Rheumatology Unit Saint Peter Hospital Fbf Rome italy
º Radiology dipartement Saint Peter Hospital Fbf Rome italy



Objective: Osteoarthritis (OA) is one of the more frequent pathology in clinical practice; hip OA is less frequent than knee or hand OA but it is more frequently symptomatic than other localizations. Although this relevant impact in clinical practice, still not conclusive data about safety and efficacy of hip viscosupplementation are reported in litterature. This study investigated on the safety and efficacy profiles of ultrasound-guided intra-articular injections of Synolis V-A (2% sodium hyaluronate 4% sorbitol, 2 ml, Anteis) in hip osteoarthritis affected patients.
Synolis V-A is a new product for intra-articular treatment of osteoarthritis; it mixed sorbitol and sodium hyaluronate to improve analgesic effect of hyaluronate and to maintain its effect until 12 months after one injection

Design: This is an open, spontaneous, prospective, monocentric, postmarketing study.
Material and methods: We enrolled adult outpatients affected by symptomatic hip OA; all patients has to show a radiographic grade 2, 3 or 4 according to Kellgren & Lawrence criteria; all patients underwent to one intra-articular (IA) injection of 4 ml (2 vials) of Synolis V-A under ultrasound guidance. Patients characteristics, such as gender, age, weight, height and BMI, smoking habit, unilateral or bilateral hip osteoarthrits involvement, radiological grade and duration of disease were evaluated. Patients were assessed at baseline and at every three months, during control visit; parameters evaluated were: Lequesne algo-functional index, Visuo Analogic Scale (VAS) for pain and NSAID consumption (calculated on the number of days patients assumed NSAID in the last month), Global patient assessment (GPA) and Global physician assessment (GPhA) and Health assessment questionnaire (HAQ). Drop out were recorded; distribution and causes of drop out were noted.

Results: We enrolled 50 patients in the study. All of them received one IA US-guided injection of Synolis V-A in the hip joint. We report preliminary data about three monts of follow-up A total of 2 drop outs were registered. A total of 50 injections was performed. Five patients were affected by bilateral hip OA (see tab 1)
No local or systemic infectious side effects were reported during the follow-up period.

Conclusions: Our preliminary data evidenced a good efficacy and safety profile of Synolis V-A for the treatment of symptomatic hip osteoarthritis after 3 months follow-up